Patents by Inventor Shibi LIKHITE

Shibi LIKHITE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY
    Publication number: 20240189453
    Abstract: The present disclosure relates to methods of treating conditions associated with a need for Merlin protein, for example due to a defective Neurofibromin 2/Merlin (NF2) gene as in neurofibromatosis type 2 (NF2). In particular. the disclosure provides gene therapy vectors to specifically treat loss of expression of the Merlin protein or reduced Merlin protein levels.
    Type: Application
    Filed: April 13, 2022
    Publication date: June 13, 2024
    Inventors: Long-Sheng Chang, Kevin Flanigan, Shibi Likhite, Kathrin Meyer
  • MATERIALS AND METHODS FOR TREATMENT OF DISORDERS ASSOCIATED WITH THE IGHMBP2 GENE
    Publication number: 20230211018
    Abstract: The disclosure provides gene therapy vectors, such as adeno-associated virus (AAV), designed for treatment of an immunoglobulin- ยต binding protein 2 (IGHMB P2)-related disorder.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 6, 2023
    Inventors: Kathrin Christine Meyer, Shibi Likhite, Kevin Foust, Brian K. Kaspar, Monica Nizzardo, Stefania Paola Corti
  • AAV-Mediated Targeting of MIRNA in the Treatment of X-Linked Disorders
    Publication number: 20230090989
    Abstract: The present disclosure relates to targeting of miRNA to activate expression of genes on the inactivated X chromosome. This gene therapy is useful for treating X-linked disorders, including Rett syndrome.
    Type: Application
    Filed: February 18, 2021
    Publication date: March 23, 2023
    Inventors: Kathrin Christine Meyer, Sanchita Bhatnagar, Jogender Tushir-Singh, Brian K. Kaspar, Shibi Likhite
  • IMPROVED DELIVERY OF GENE THERAPY VECTORS TO RETINAL CELLS USING A GLYCOSIDE HYDROLASE ENZYME
    Publication number: 20220233655
    Abstract: The present disclosure relates to methods of targeting specific cell types within the retina using optimized gene therapy vectors in combination with a glycoside hydrolase enzyme, such as neuraminidase. In particular, the disclosure provides gene therapy vectors administered with a glycoside hydrolase enzyme to specifically target retinal cells and methods of treating visual impairment, retinal degeneration and vision-related disorders.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 28, 2022
    Inventors: Kathrin Christine Meyer, Shibi Likhite
  • OPTIMIZED GENE THERAPY TARGETING RETINAL CELLS
    Publication number: 20220226507
    Abstract: The present disclosure relates to methods of targeting specific cell types within the retina using optimized gene therapy vectors. In particular, the disclosure provides gene therapy vectors to specifically target retinal cells and methods of treating visual impairment, retinal degeneration and vision-related disorders such as CLN disease.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 21, 2022
    Inventors: Kathrin Christine Meyer, Shibi Likhite, Brian K. Kaspar, Jill M. Weimer
  • GENE THERAPY FOR TREATING OR PREVENTING VISUAL EFFECTS IN BATTEN DISEASE
    Publication number: 20220193259
    Abstract: The present disclosure relates to gene therapy methods of preserving photoreceptors and/or inhibiting or preventing retinal degeneration in Batten disease patients, including recombinant adeno-associated vims (rAAV) delivery of a neuronal ceroid lipofuscinosis neuronal 6 (CLN6) polynucleotide.
    Type: Application
    Filed: April 15, 2020
    Publication date: June 23, 2022
    Inventors: Kathrin Meyer, Shibi Likhite, Brian K. Kaspar, Jill M. Weimer
  • GENERATION OF CHIMERIC ANTIGEN RECEPTOR (CAR)-PRIMARY NK CELLS FOR CANCER IMMUNOTHERAPY USING A COMBINATION OF CAS9/RNP AND AAV VIRUSES
    Publication number: 20220177917
    Abstract: Disclosed are methods for genetically engineering cells using Adeno-associated viral (AAV) delivery of a CRISPR/CAS9 system and ribonucleoproteins for integration.
    Type: Application
    Filed: March 27, 2020
    Publication date: June 9, 2022
    Inventors: Dean Anthony LEE, Kathrin Christine MEYER, Meisam Naeimi KARAROUDI, Shibi LIKHITE